Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Research Article
Single Nucleotide Polymorphism of MSH3 Gene Alters Head and Neck Squamous-Cell Carcinoma Risk in North-India

Suresh Kumar Yadav, Shalini Gupta, Madan Lal Brahma Bhatt, Durga Prasad Mishra, Dayalanand Roy and Somali Sanyal

International Journal of Cancer Research, 2018, 14(1), 27-31.


Background and Objective: Squamous cell carcinoma of head and neck (SCCHN) is attributed by tobacco chewing and smoking which are known to cause DNA damage. Eventually such damage if get fixed as mutation can enhance the risk of SCCHN. These damaged are repaired by DNA repair protein such as MutS Homolog 3 (MSH3). Therefore, genetic polymorphisms in MSH3 gene which affect its efficiency can modulate the risk of cancer including SCCHN. The present study examined the association of MSH3 rs26279 G>A polymorphism with the risk and clinical outcome of SCCHN. Materials and Methods: One Hundred and eighty six patients of SCCHN and 188 cancer free healthy control subjects were genotyped by PCR-RFLP method. Genotypes of SCCHN patients were further correlated with their disease status including stage, grade, tumour size, metastasis and lymph node involvement. Results: The risk of developing SCCHN was 2 times more with GG genotype compared to AA genotype for MSH3 G>A polymorphism (OR = 2.61, 95% CI 1.06-6.73, p-value = 0.05). The G allele itself imparted significantly higher risk for developing SCCHN compared to A allele (OR = 1.55, 95% CI 1.08-2.26, p-value = 0.01). Variant allele genotype (AG+GG) of MSH3 G>A polymorphism were associated with the development of high staged (III+IV) and large sized tumour (T3+T4). Compared to the common allele genotype (AA) the risk of developing high staged and large sized tumour were 2 times more with variant allele genotype (OR = 2.34, 95% CI = 1.19-4.58, p-value = 0.02 and OR = 2.14, 95% CI 1.32-4.40, p-value = 0.006, respectively). Conclusion: Result from the present study suggested that MSH3 rs26279 G>A polymorphism cannot only modify the risk for developing SCCHN but also the clinical status of tumour in SCCHN patients.

ASCI-ID: 36-316

Cited References Fulltext

Related Articles

Prevalence of Oral and Pharyngeal Cancers in Kermanshah Province, Iran: A Ten-year Period

International Journal of Cancer Research, 2016, 12(3-4), 169-175.

Mutations in XRCC1 Gene Alters the Genetic Risks of Head and Neck Cancer Patients

International Journal of Cancer Research, 2009, 5(2), 58-68.

Vitamin D Receptor Gene Polymorphisms as a Predictive Risk Factor for Hepatocellular Carcinoma Development and Severity in Chronic Hepatitis B

International Journal of Cancer Research, 2017, 13(1), 26-35.

Novel CYP3A4 Gene Polymorphisms in Post Chemo Breast Cancer Patients

International Journal of Cancer Research, 2006, 2(4), 358-366.

A Novel Approach to Acute Lymphoblastic Leukemia in Adults: Association Analysis of Polymorphisms in Vascular Endothelial Growth Factor (VEGF) Gene and Clinical Outcome

International Journal of Cancer Research, 2015, 11(2), 93-103.